Can Lamictal (lamotrigine) cause gastrointestinal (GI) problems?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Lamictal Cause Gastrointestinal Problems?

Yes, lamotrigine (Lamictal) can cause gastrointestinal side effects, though these are generally mild and primarily include nausea and diarrhea. 1

Common GI Side Effects

The most frequently reported gastrointestinal adverse events with lamotrigine are primarily neurological, gastrointestinal, and dermatological in nature, with GI symptoms being common but typically not severe 1:

  • Nausea is one of the most common adverse events reported with lamotrigine therapy 1, 2
  • Diarrhea occurs in some patients and was specifically noted as significantly lower in lamotrigine-treated patients compared to lithium-treated patients in bipolar disorder studies 2
  • These GI symptoms are generally well-tolerated and do not typically require treatment discontinuation 1

Clinical Context and Severity

The gastrointestinal side effects of lamotrigine are considered mild compared to other medications and are not typically a major clinical concern:

  • In comparative studies, lamotrigine demonstrated better GI tolerability than lithium, with significantly lower incidences of diarrhea 2
  • The most common reason for treatment withdrawal with lamotrigine is skin rash (occurring in approximately 10% of patients), not gastrointestinal problems 1
  • Headache, nausea, infection, and insomnia were the most common adverse events in maintenance studies, but these were generally manageable 2

Important Considerations

Lamotrigine's GI effects can be influenced by gastrointestinal anatomy changes:

  • Bariatric surgeries (Roux-en-Y gastric bypass and sleeve gastrectomy) can affect lamotrigine pharmacokinetics through alterations in GI physiology, with RYGB showing average increases in drug exposure of 38% at one month and 32% at 12 months postoperatively 3
  • Therapeutic drug monitoring should be used after bariatric surgery due to substantial interindividual variation in pharmacokinetic changes 3

Clinical Management

If GI symptoms occur with lamotrigine, they typically do not require specific intervention beyond symptomatic management:

  • The slow dose titration schedule recommended to minimize rash risk may also help reduce GI side effects 1
  • Unlike some other medications, lamotrigine does not cause significant weight gain, which is an advantage for long-term tolerability 2
  • GI symptoms are generally transient and improve with continued therapy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.